세계의 CD20 항체 시장 보고서(2025년)

CD20 antibodies are monoclonal antibodies that specifically target CD20, a protein present on the surface of B cells, a type of white blood cell involved in the immune response. These antibodies are primarily used to treat conditions associated with abnormal B-cell function, including cancers and autoimmune diseases. Their primary role is to bind to the CD20 protein on B cells and initiate their destruction.

The primary end users of CD20 antibodies include hospitals, specialty clinics, ambulatory surgical centers, and others. These antibodies are utilized in various applications such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blot, immunoprecipitation, and immunofluorescence. CD20 antibodies are categorized into two main types, monoclonal and polyclonal antibodies. Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific targets, such as the CD19 antigen found on B cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The CD-20 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-20 antibody market statistics, including CD-20 antibody industry global market size, regional shares, competitors with a CD-20 antibody market share, detailed CD-20 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-20 antibody industry. This CD-20 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cd20 antibody market size has grown rapidly in recent years. It will grow from $9.94 billion in 2024 to $10.96 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing prevalence of b-cell malignancies, rising incidence of autoimmune diseases, growing demand for targeted therapies, increasing approvals of biosimilars, rising healthcare expenditure, improving healthcare infrastructure and increasing awareness of immunotherapy benefits.

The cd20 antibody market size is expected to see rapid growth in the next few years. It will grow to $16.09 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to rising demand for advanced cancer immunotherapies, increasing prevalence of autoimmune disorders, growing adoption of biosimilar CD20 antibodies, expanding applications in combination therapies, increasing investment in biopharmaceutical research, growing awareness of personalized medicine. Major trends in the forecast period include development of next-generation CD20 antibodies, advancements in antibody-drug conjugates, integration of artificial intelligence in antibody design, improvements in bispecific antibody technology, rise of CAR-T cell therapies targeting CD20, adoption of nanotechnology for enhanced delivery, advancements in high-throughput screening methods.

The forecast of 10.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. hematology care by inflating prices of rituximab biosimilars and CD20-targeting CAR-T therapies developed in South Korea and Germany, resulting in delayed lymphoma treatments and higher oncology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of B-cell malignancies is anticipated to drive the expansion of the CD20 antibody market in the coming years. B-cell malignancies refer to the increasing incidence of cancers affecting B cells, a type of white blood cell crucial to the immune response. Various factors contribute to this rise, including an aging population, genetic predispositions, environmental exposures, lifestyle changes, advancements in detection methods, and alterations in the immune system. CD20 antibodies, such as rituximab, play a critical role in targeting and eliminating malignant B-cells in conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, thereby improving treatment outcomes. For instance, a 2024 report by the American College of Cardiology, a US-based nonprofit medical association, estimates that in 2025, approximately 80,350 individuals (45,140 males and 35,210 females), including both adults and children, will be diagnosed with non-Hodgkin lymphoma (NHL). Furthermore, around 19,390 people (11,060 males and 8,330 females) are projected to succumb to this cancer. As a result, the increasing occurrence of B-cell malignancies is propelling the expansion of the CD20 antibody market.

Leading companies in the CD20 antibody market are prioritizing technological advancements such as biosimilars to improve treatment accessibility, lower healthcare costs, and meet the growing need for affordable and effective therapies for B-cell malignancies and autoimmune diseases. Biosimilars are biologic medical products that closely resemble an already approved reference product without any significant differences in safety, purity, or efficacy. For example, in July 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate. The company intends to collaborate with the USFDA to resolve all concerns within the designated timeframe, aiming to introduce the biosimilar rituximab to patients in the United States. Rituximab biosimilar functions by targeting the CD20 protein on the surface of B-cells, triggering a response that leads to the destruction of these abnormal or overactive B-cells.

In October 2024, GSK plc, a UK-based biopharmaceutical and biotechnology company, acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager (TCE) currently in clinical development, from Chimagen Biosciences for an undisclosed sum. Through this acquisition, GSK aims to develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential for expansion into related autoimmune conditions. Chimagen Biosciences, a China-based clinical-stage biotechnology firm, specializes in discovering and developing novel multi-specific T cell-engagers and NK cell-engagers.

Major players in the CD20 antibody market are F Hoffmann-La Roche AG, Merck & Co Inc, Thermo Fisher Scientific Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Genentech Inc, Bio-Rad Laboratories Inc, Genmab A/S, Bio-Techne, LFB Biotechnologies SA, Abcam Limited, Sino Biological Inc, Mylan NV, Immunomedics Inc, Spectrum Pharmaceuticals Inc, MyBiosource Inc, IGM Biosciences Inc, and TG Therapeutics Inc.

North America was the largest region in the CD20 antibody market in 2024. The regions covered in CD20 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD20 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD20 antibody market consists of sales of rituximab, obinutuzumab, and ofatumumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD20 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cd20 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd20 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cd20 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibody; Polyclonal Antibody
• 2) By Application: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Western Blot; Immunoprecipitation; Immunofluorescence
• 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Monoclonal Antibody: Rituximab; Obinutuzumab; Ofatumumab
• 2) By Polyclonal Antibody: Conventional Polyclonal Antibodies; Human Polyclonal Antibodies; Recombinant Polyclonal Antibodies
• Companies Mentioned: F Hoffmann-La Roche AG; Merck & Co Inc; Thermo Fisher Scientific Inc; Novartis AG; GlaxoSmithKline plc; Amgen Inc; Teva Pharmaceutical Industries Ltd; Biogen Inc; Genentech Inc; Bio-Rad Laboratories Inc; Genmab A/S; Bio-Techne; LFB Biotechnologies SA; Abcam Limited; Sino Biological Inc; Mylan NV; Immunomedics Inc; Spectrum Pharmaceuticals Inc; MyBiosource Inc; IGM Biosciences Inc; TG Therapeutics Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. CD20 Antibody Market Characteristics

3. CD20 Antibody Market Trends And Strategies

4. CD20 Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global CD20 Antibody Growth Analysis And Strategic Analysis Framework

• 5.1. Global CD20 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global CD20 Antibody Market Growth Rate Analysis
• 5.4. Global CD20 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global CD20 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global CD20 Antibody Total Addressable Market (TAM)

6. CD20 Antibody Market Segmentation

• 6.1. Global CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody
• Polyclonal Antibody
• 6.2. Global CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flow Cytometry
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Western Blot
• Immunoprecipitation
• Immunofluorescence
• 6.3. Global CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global CD20 Antibody Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab
• Obinutuzumab
• Ofatumumab
• 6.5. Global CD20 Antibody Market, Sub-Segmentation Of Polyclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Polyclonal Antibodies
• Human Polyclonal Antibodies
• Recombinant Polyclonal Antibodies

7. CD20 Antibody Market Regional And Country Analysis

• 7.1. Global CD20 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global CD20 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific CD20 Antibody Market

• 8.1. Asia-Pacific CD20 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China CD20 Antibody Market

• 9.1. China CD20 Antibody Market Overview
• 9.2. China CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India CD20 Antibody Market

• 10.1. India CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan CD20 Antibody Market

• 11.1. Japan CD20 Antibody Market Overview
• 11.2. Japan CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia CD20 Antibody Market

• 12.1. Australia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia CD20 Antibody Market

• 13.1. Indonesia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea CD20 Antibody Market

• 14.1. South Korea CD20 Antibody Market Overview
• 14.2. South Korea CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe CD20 Antibody Market

• 15.1. Western Europe CD20 Antibody Market Overview
• 15.2. Western Europe CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK CD20 Antibody Market

• 16.1. UK CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany CD20 Antibody Market

• 17.1. Germany CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France CD20 Antibody Market

• 18.1. France CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy CD20 Antibody Market

• 19.1. Italy CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain CD20 Antibody Market

• 20.1. Spain CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe CD20 Antibody Market

• 21.1. Eastern Europe CD20 Antibody Market Overview
• 21.2. Eastern Europe CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia CD20 Antibody Market

• 22.1. Russia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America CD20 Antibody Market

• 23.1. North America CD20 Antibody Market Overview
• 23.2. North America CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA CD20 Antibody Market

• 24.1. USA CD20 Antibody Market Overview
• 24.2. USA CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada CD20 Antibody Market

• 25.1. Canada CD20 Antibody Market Overview
• 25.2. Canada CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America CD20 Antibody Market

• 26.1. South America CD20 Antibody Market Overview
• 26.2. South America CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil CD20 Antibody Market

• 27.1. Brazil CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East CD20 Antibody Market

• 28.1. Middle East CD20 Antibody Market Overview
• 28.2. Middle East CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa CD20 Antibody Market

• 29.1. Africa CD20 Antibody Market Overview
• 29.2. Africa CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. CD20 Antibody Market Competitive Landscape And Company Profiles

• 30.1. CD20 Antibody Market Competitive Landscape
• 30.2. CD20 Antibody Market Company Profiles
  • 30.2.1. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. CD20 Antibody Market Other Major And Innovative Companies

• 31.1. Amgen Inc
• 31.2. Teva Pharmaceutical Industries Ltd
• 31.3. Biogen Inc
• 31.4. Genentech Inc
• 31.5. Bio-Rad Laboratories Inc
• 31.6. Genmab A/S
• 31.7. Bio-Techne
• 31.8. LFB Biotechnologies SA
• 31.9. Abcam Limited
• 31.10. Sino Biological Inc
• 31.11. Mylan NV
• 31.12. Immunomedics Inc
• 31.13. Spectrum Pharmaceuticals Inc
• 31.14. MyBiosource Inc
• 31.15. IGM Biosciences Inc

32. Global CD20 Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CD20 Antibody Market

34. Recent Developments In The CD20 Antibody Market

35. CD20 Antibody Market High Potential Countries, Segments and Strategies

• 35.1 CD20 Antibody Market In 2029 - Countries Offering Most New Opportunities
• 35.2 CD20 Antibody Market In 2029 - Segments Offering Most New Opportunities
• 35.3 CD20 Antibody Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer